Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response.

Gastroenterology - 1 Feb 2010

Ferenci Peter, Laferl Hermann, Scherzer Thomas-Matthias, Maieron Andreas, Hofer Harald, Stauber Rudolf, Gschwantler Michael, Brunner Harald, Wenisch Christoph, Bischof Martin, Strasser Michael, Datz Christian, Vogel Wolfgang, Löschenberger Karin, Steindl-Munda Petra

Abstract excerpt

BACKGROUND & AIMS: This randomized multicenter trial evaluated individualization of treatment duration with peginterferon alfa-2a 180 microg/wk plus ribavirin 1000/1200 mg/day in patients with chronic hepatitis C genotype 1/4 based on the rapidity of virologic response (VR). METHODS: Patients with a rapid VR (RVR; undetectable hepatitis C virus [HCV]-RNA level (<50 IU/mL at week 4) were treated for 24 weeks,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Viral
Share to Hepatitis C

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Polyethylene Glycols

Share to Ribavirin

Share to Secondary Prevention

Share to Virus Replication

Source

Identifiers

PMID: 19909752
DOI: 10.1053/j.gastro.2009.10.058

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response.PMID 19909752Read ↗

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.Semantic proximity Read ↗

Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin.Semantic proximity Read ↗

Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.Semantic proximity Read ↗

Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.Semantic proximity Read ↗

Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin.Semantic proximity Read ↗

Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection.Semantic proximity Read ↗

Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future.Semantic proximity Read ↗

Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis.Semantic proximity Read ↗

Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response.Semantic proximity Read ↗

Tailoring treatment duration to 12 to 16 weeks in hepatitis C genotype 2 or 3 with rapid virologic response: systematic review and meta-analysis of randomized controlled trials.Semantic proximity Read ↗

Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders.Semantic proximity Read ↗

Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.